Scarica l'app Stockscreener
2.69
5.61%
-0.16
Dopo l'orario di chiusura:
2.64
-0.05
-1.86%
Precedente Chiudi:
$2.85
Aprire:
$2.81
Volume 24 ore:
35,074
Relative Volume:
0.58
Capitalizzazione di mercato:
$30.09M
Reddito:
-
Utile/perdita netta:
$-18.92M
Rapporto P/E:
-1.5348
EPS:
-1.7527
Flusso di cassa netto:
$-16.86M
1 W Prestazione:
+5.08%
1M Prestazione:
-19.94%
6M Prestazione:
-39.55%
1 anno Prestazione:
-44.07%
Intervallo 1D:
$2.6301
$2.88
Intervallo di 1 settimana:
$2.575
$2.9799
Portata 52W:
$2.53
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Nome
Lantern Pharma Inc
Settore
Industria
Telefono
972-277-1136
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
2.69 | 31.88M | 0 | -18.92M | -16.86M | -1.7527 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-07 | Iniziato | H.C. Wainwright | Buy |
Lantern Pharma Inc Borsa (LTRN) Ultime notizie
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition - Yahoo Finance
Aug Gainers: Can Lantern Pharma Inc. stock sustain institutional interestMarket Trend Report & Weekly High Potential Stock Alerts - mfd.ru
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026 - Business Wire
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Asheville Citizen Times
Growth Report: How much upside does GWRE haveMarket Sentiment Report & Daily Entry Point Alerts - baoquankhu1.vn
Patterns Watch: Is Lantern Pharma Inc stock undervalued right nowJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26 - Corpus Christi Caller-Times
Lantern Pharma to Set Up AI Center of Excellence in Bengaluru to Scale RADR Platform - Digital Health News
FDA grants orphan drug designation to Lantern Pharma’s LP-284 for sarcomas - Investing.com Nigeria
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas - PharmiWeb.com
Lantern Pharma (LTRN) Secures Orphan Drug Designation for LP-284 - GuruFocus
Lantern Pharma Establishes New AI Centre Of Excellence, Agentic Labs Hub In Bengaluru - Voice Of HealthCare
Lantern Pharma Expands Global AI Footprint with Bengaluru Center of Excellence - eHealth Magazine
Critical Comparison: Lantern Pharma (NASDAQ:LTRN) versus Praxis Precision Medicines (NASDAQ:PRAX) - Defense World
FDA Grants Orphan Drug Status to Lantern Pharma's Treatment for Sarcoma (LTRN) - GuruFocus
Lantern Pharma launches AI Center of Excellence in Bengaluru to scale precision drug discovery globally - Indian Pharma Post
Recap Report: Whats the outlook for Lantern Pharma Incs sectorQuarterly Risk Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Lantern Pharma establishes AI Centre of Excellence and Advanced Agentic Labs in Bengaluru - BioSpectrum India
History Review: Is Lantern Pharma Inc stock a hidden gemGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RAD - PharmiWeb.com
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies - 01net
Lantern Pharma IncEstablishes Ai Center Of Excellence In Bengaluru - TradingView — Track All Markets
Is Lantern Pharma Inc. stock a contrarian buyJuly 2025 Highlights & AI Forecasted Stock Moves - Улправда
Why Lantern Pharma Inc. stock attracts global investorsEarnings Date Calendar & Top Analyst Picks Available for Free - Улправда
Lantern Pharma (NASDAQ:LTRN) Stock Price Up 6.2% – What’s Next? - Defense World
What analysts say about Lantern Pharma Inc stockMarket Capitalization Trends & Superior Capital Growth - earlytimes.in
Lantern Pharma Inc Stock Analysis and ForecastMACD Histogram Signals & Fast Profit Trading Strategies - earlytimes.in
Is Lantern Pharma Inc a good long term investmentResistance Breakout Alerts & Learn to Trade with Real-Time Feedback - earlytimes.in
Sentiment Recap: Is Lantern Pharma Inc. stock a safe buy before earningsWeekly Profit Summary & Free Expert Approved Momentum Trade Ideas - moha.gov.vn
What Wall Street predicts for Lantern Pharma Inc. stock priceJuly 2025 Update & Verified Entry Point Signals - Улправда
Lantern Pharma’s AI Bet Needs 2026 Trial Wins - Finimize
What momentum indicators show for Lantern Pharma Inc. stockEarnings Miss & AI Optimized Trade Strategies - DonanımHaber
Why Lantern Pharma Inc. stock remains resilientNew Guidance & Target Return Focused Stock Picks - Улправда
Lantern Pharma (NASDAQ:LTRN) Shares Down 6.4% – Should You Sell? - Defense World
Lantern Pharma Earnings Notes - Trefis
Analyst Upgrade: Why Lantern Pharma Inc stock is rated strong buyTrade Entry Summary & Daily Chart Pattern Signals - moha.gov.vn
Lantern Pharma announces LP-184 clinical trial met all primary endpoints - MSN
Lake Street Remains a Buy on Lantern Pharma (LTRN) - The Globe and Mail
Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors - Digital Journal
Will Lantern Pharma Inc. stock benefit from automationTreasury Yields & AI Forecasted Stock Moves - Newser
Will Lantern Pharma Inc. stock rally after Fed decisionsPortfolio Return Report & Low Volatility Stock Suggestions - Newser
Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial - Proactive financial news
Lantern’s cancer drug LP-184 shows promise in phase 1a trial - Investing.com Australia
Lantern Pharma (LTRN) Advances with Promising Clinical Insights from Phase 1a Study - GuruFocus
Lantern Pharma Inc Azioni (LTRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):